Share to linkedin
This is a terrible result for Alzheimer’s patients who had hoped that this was the drug that would finally succeed in treating AD. But the demise of aducanumab is also disastrous for Biogen which had expended an enormous amount of resources into this program, likely at the expense of other opportunities. It was a risky bet and one for which Wall Street has delivered a punishing blow. Biogen’s stock dropped by nearly 30% shortly after announcing the disappointing aducanumab results.
Source: News Formal (newsformal.com)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Source: Reuters - 🏆 2. / 97 Read more »
Biogen scraps Alzheimer drug trials, wiping $17 billion off its market valueReuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for t... This sucks. Did they forget? 😂
Source: Reuters - 🏆 2. / 97 Read more »
Biogen scraps two Alzheimer drug trials, wipes $18 billion from market valueBiogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex... I'll remember this. Why don’t they learn how to use CBDa? I take issue with the quote attributed to Guggenheim analyst, Yaris Suneja. You would not consider investment in Alzheimer ‘s research a “waste” if a loved one were so afflicted. This is a devastating disease. It takes a brave company to find an answer.
Source: Reuters - 🏆 2. / 97 Read more »
Breakingviews TV: Biogen failThe abandonment of Biogen’s Alzheimer’s drug, which cost it $18 billion in market value, follows the failure of similar efforts by others. It’s a potentially huge market, but a tough one to crack. Rob Cyran explains why investors may have been too... Reuters rob_cyran Elizabeth Holmes again? Reuters rob_cyran Cost consumers not Biogen they will pass the loss of their failure down to the consumer with higher prices on other drugs.
Source: Breakingviews - 🏆 470. / 51 Read more »
Here are the biggest analyst calls of the day: Biogen, Apple, Micron, & moreHere are the biggest calls on Wall Street on Thursday
Source: CNBC - 🏆 12. / 72 Read more »
Biogen stock plunge shows 'investment model in drug development is all wrong,' says former Aetna CEOFormer Aetna Chairman and CEO Mark Bertolini says investors currently are trading 'on a basis that says, 'does this drug work today? Did this trial pass today?'''
Source: CNBC - 🏆 12. / 72 Read more »
Biogen heads for the worst day in a decade after ending trial for blockbuster Alzheimer's drugShares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab. Literally no one expected it to be a blockbuster. No quick fix for Trump
Source: CNBC - 🏆 12. / 72 Read more »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
Source: MarketWatch - 🏆 3. / 97 Read more »
Biogen loses same Alzheimer’s bet others have lostThe failures of similar drugs in formal trials meant Biogen’s effort was always a long shot. Yet ditching it vaporized $18 bln, or over a quarter, of the biotech’s value. The giant market for a therapy and the fear of missing out lured in both the company and Wall Street. ReutersBiz rob_cyran This will continue to happen, again and again. Focus ought to be in industry and long-term planning, understanding of trends. Not in magic bullets and 24x5s.
Source: Breakingviews - 🏆 470. / 51 Read more »
Stocks making the biggest moves midday: Levi Strauss, Biogen, Micron & moreThese are the stocks posting the largest moves midday Thursday. Liberals trying to think about stocks
Source: CNBC - 🏆 12. / 72 Read more »
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
Source: CNBC - 🏆 12. / 72 Read more »